Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
07 mai 2020 08h30 HE
|
ARCA biopharma, Inc.
New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence ° 26% reduction in total time spent...
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
06 mai 2020 16h30 HE
|
ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
Conformal Medical Announces First Left Atrial Appendage Closures Performed Under Conscious Sedation with its CLAAS Technology at AF Symposium 2020
22 janv. 2020 08h50 HE
|
Conformal Medical, Inc.
NASHUA, N.H., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Conformal Medical, Inc. announced today the presentation of the first left atrial appendage closure (LAAC) cases with its unique CLAAS® Technology in...
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
12 sept. 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
11 sept. 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
01 août 2019 16h30 HE
|
ARCA biopharma, Inc.
FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)PRECISION-AF...
Atrial Fibrillation Market To Reach USD 14.68 Billion By 2026| Reports And Data
27 mai 2019 13h07 HE
|
Reports And Data
Increase in number of heart diseases coupled with technological advancements globally, are the major factors influencing market growth. Market Size – USD 5.08 billion in 2018, Market Growth - CAGR of...
ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure
13 mai 2019 09h00 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 13, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure
01 mai 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 01, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial
23 avr. 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., April 23, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...